ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO360

Vascular Abnormalities in CKD Patients

Session Information

Category: Hypertension and CVD

  • 1402 Hypertension and CVD: Clinical, Outcomes, and Trials


  • Hojs, Nina, University Clinical Centre Maribor, Maribor, Slovenia
  • Junarta, Joey, St. George''s, University of London, London, United Kingdom
  • Ramphul, Robin, St. George's University Hospitals NHS Foundation Trust, Worthing, United Kingdom
  • Lowe-Jones, Racquel M., St George''s University Hospital, London, United Kingdom
  • Kaski, Juan carlos, SGUL, LONDON, United Kingdom
  • Banerjee, Debasish, St Georges Hospital and St Georges University of London, Wimbledon, lONDON, United Kingdom

CKD patients suffer from excess vascular events. The exact nature of vascular abnormalities and their progression is unknown. The aim of our study was to compare vascular abnormalities and its progression in 3-6 months in different CKD groups and healthy controls.


A detailed vascular assessment was performed in clinically stable patients (21 CKD stage 2-4, 14 haemodialysis (HD), 22 transplant (TX)) and 21 healthy controls in a quiet, temperature controlled vascular laboratory; at baseline and 3-6 months. Data were analysed with SPSS version 25, P value <0.05 was considered significant.


The carotid intima media thickness (CIMT) differed significantly between all groups at baseline and after 3-6 months. As expected, the lowest values were present in healthy controls and the highest in CKD2-4 and HD patients. Ankle brachial index (ABI) significantly differed between groups at baseline, but not after 3-6 months. Brachial flow mediated dilatation (FMD) didn't differ between groups at baseline or on follow up. Pulse wave velocities (PWV) were significantly different between different groups, with the highest values in HD and CKD2-4 patients and the lowest values in healthy controls.
During 3-6 months CIMT increased significantly only in TX patients. ABI significantly decreased in 3-6 months in the CKD2-4 patients. FMD decreased in 3-6 months in TX patients. PWV didn't change significantly in 3-6 months in all groups.


CKD2-4, HD, TX patients and healthy controls differ significantly in CIMT, ABI and PWV, with the most abnormal values present in HD patients. Progression of cardiovascular disease in this short term follow up was variable, with worsening of FMD and CIMT in TX patients.

P value
CIMT1 (mm)7.05±1.446.86±1.335.89±0.925.55 ±1.030.000*
CIMT2 (mm)7.42±1.547.08±0.766.13±0.985.723±1.340.001*
P value (pair t-test)
P value (pair t-test)
FMD1 (%)3.60±2.483.03±2.074.07±4.064.41±2.820.577
FMD2 (%)2.21±1.742.11±1.712.69±2.193.51±2.730.292
P value (pair t-test)
PWV1 (m/s)10.46±2.5411.88±2.547.88±1.806.98±1.270.000*
PWV2 (m/s)10.26±2.4411.35±2.858.41±2.227.17±1.500.000*
P value (pair t-test)